CN Patent

CN101443050A — 治疗视觉失调中使用的补体结合适体和抗-c5药物

Assigned to Archemix Corp · Expires 2009-05-27 · 17y expired

What this patent protects

通过施用有效剂量的药物抑制主体中补体成分以治疗补体－介导的眼部失调的方法，其中选择的实施方案中，所述的药物是一种抗－补体适体，优选实施方案中，是一种抗－C5适体。

USPTO Abstract

通过施用有效剂量的药物抑制主体中补体成分以治疗补体－介导的眼部失调的方法，其中选择的实施方案中，所述的药物是一种抗－补体适体，优选实施方案中，是一种抗－C5适体。

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: CN101443050A
Jurisdiction: CN
Classification: —
Expires: 2009-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Archemix Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.